Zurich Coronavirus Vaccination Cohort: an observational study to assess longer-term immune responses and health status after coronavirus (COVID-19) vaccination in Zurich, Switzerland

Not Applicable

Conditions: COVID-19 (SARS-Cov-2 infection)
Infections and Infestations
COVID-19 (SARS-CoV-2 infection)

Registration Number: ISRCTN15499304

Lead Sponsor: niversity of Zurich

Brief Summary: 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37095137/ (added 14/05/2024)

Detailed Description: Not available

Recruitment & Eligibility

Status: Ongoing

Sex: All

Target Recruitment: 575

Inclusion Criteria

1. Individuals receiving any of the SARS-CoV-2 vaccines approved in Switzerland at the Corona Center of the UZH
2. Aged =18 years,
3. Able to follow the study procedures
4. Providing informed consent

Exclusion Criteria

1. Having insufficient knowledge of the German language
2. Individuals whose primary residence is outside of the Canton of Zurich
3. Previously received SARS-CoV-2 vaccine

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Current primary outcome measures as of 08/06/2022:<br>Measured using blood samples:<br>1. Presence of anti-SARS-CoV-2 IgG antibodies before receiving the first dose of a vaccine (baseline) and at 3-4 weeks, 6 weeks, 3 months, 6 months, 12 months, and every 6 months up to 3 years after baseline<br>2. Presence of SARS-CoV-2 antigen-specific T cells before receiving the first dose of a vaccine (baseline) and at 3-4 weeks, 6 weeks, 3 months, 6 months, 12 months, and every 6 months up to 3 years after baseline<br>_____<br><br>Previous primary outcome measures:<br>Measured using blood samples:<br>1. Presence of anti-SARS-CoV-2 IgG antibodies before receiving the first dose of a vaccine (baseline), at 3-4 weeks, at 6 weeks, and at 3, 6 and 12 months after baseline<br>2. Presence of SARS-CoV-2 antigen-specific T cells before receiving the first dose of a vaccine (baseline), and at 3-4 weeks, at 6 weeks, and at 3, 6 and 12 months after baseline

Secondary Outcome Measures